90 seconds...., page-13

First 13 Last

Share
Profile

Follow
angomango88

592 Posts.

149

29/09/22

11:10

Post #: 63939304
Share

Originally posted by tradeprofits: ↑

I hope for you guys too, I really don't like seeing people taken for a ride and sadly all signs point to this being a dodgy company.

If Rex was anything viable it wouldv'e been done already by someone else, and if somehow DLC found value in it that everyone else smarter missed, DLC would have been agressively pursuing it - but they weren't, they were doing other things since Oct last year until just now (MOM).

Sometimes you have to face facts and not hope or talk of hypothetical pumps. There really is nothing going for MOM. Sometimes it really is all smoke and mirrors.
> Look at the back scratching
> Look at the Calvista grab for an unfair value. Why did 40% vote against this?
> Look at the web
> Look at the history
> Look at the trading halt and how that affected shareholder value when U308 was a booming theme (note *theme* - this is why DLC pivoted)
....it worked. We bought
> Look at Nabberu
....(this one really is an absolute joke - and even if you believe in Rex, what has Nabberu purchase got to do with it? ....what has it got to do with then?)

Is this a lifestyle company? If it walks like a duck.

Just because a company is drilling doesn't mean it's viable. If they weren't planning to drill what would you think? Maybe they know this?

Are you hoping they will find something when they drill? Hope being the operative word. Look at the news, they hyped the U308 with the sample to be sent for testing, then..... nothing.

Lieftyle companies are a disgrace, they exist to transfer wealth from retail shareholders to themselves rather than create shareholder wealth (ask yourself if you have seen evidence of this with DLC/MOM).

Don't kid yourself with Directors or CPS having skin in the game - ask yourself if this skin is real skin and real risk, or if it serves a purpose (funding the lifestyle - salaries, options, fees, free shares, unfair asset grabs, worthless acquisitions). The money for them is not in the imaginary pump you are hoping for.

Expand

We know this. We just have to wait until the spike happens, that's all.

MOM Price at posting: 1.4¢ Sentiment: Hold Disclosure: Held
4 Upvote

2 Great analysis

Reply

Top Stories

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 36 more messages in this thread...

First 13 Last

Add MOM (ASX) to my watchlist

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $3.235M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$9.001K	2.250M

Buyers (Bids)

No.	Vol.	Price($)
7	2592092	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	9833286	3

View Market Depth

No.	Vol.	Price($)
7	2592092	0.003
4	10100000	0.002
4	21950000	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.005	9833286	3
0.006	1307472	6
0.007	939850	2
0.008	2875000	2
0.009	700000	1

Last trade - 11.09am 02/10/2024 (20 minute delay)

MOM (ASX) Chart

90 seconds...., page-13

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

90 seconds...., page-13

Top Stories

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News